Zyprexa Relprevv

Delirium, Delusional Parasitosis, Schizophrenia + 11 more

Treatment

4 FDA approvals

20 Active Studies for Zyprexa Relprevv

Treatment for

Delirium

What is Zyprexa Relprevv

OlanzapineThe Generic name of this drug

Treatment SummaryOlanzapine is an antipsychotic medication that belongs to a class of drugs called atypical antipsychotics. It was approved for use in the United States in 1996 and is known to be effective in treating mental illnesses with fewer side effects and drug interactions compared to other antipsychotics. Olanzapine is very similar to the drug clozapine, with two additional methyl groups and no chloride content.

Zyprexais the brand name

image of different drug pills on a surface

Zyprexa Relprevv Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zyprexa

Olanzapine

1996

546

Approved as Treatment by the FDA

Olanzapine, otherwise known as Zyprexa, is approved by the FDA for 4 uses which include Bipolar Disorder and Unipolar Depression .

Bipolar Disorder

Used to treat Bipolar Disorder With Manic or Mixed Episodes in combination with Lithium cation

Unipolar Depression

Used to treat Major depressive disorder, recurrent episode in combination with Fluoxetine

Mental Depression

Used to treat Acute Depressive Episode in combination with Fluoxetine

Bipolar Disorder

Used to treat Bipolar 1 Disorder in combination with Fluoxetine

Effectiveness

How Zyprexa Relprevv Affects PatientsOlanzapine works by targeting two different receptors in the brain - the dopamine D2 receptor and the serotonin 5HT2A receptor. This action has been found to be effective in reducing symptoms of schizophrenia, bipolar disorder in adults and acute episodes of bipolar disorder in adolescents. It has also been demonstrated to be successful in reducing chemotherapy-induced nausea and vomiting. Studies have shown that olanzapine can produce a complete response in 84% of individuals and control nausea and vomiting for over 80%.

How Zyprexa Relprevv works in the bodyOlanzapine works by blocking various receptors in the brain, including dopamine and serotonin receptors. Blocking dopamine receptors in the mesolimbic pathway is key to its activity. Olanzapine binds to these receptors and makes it harder for dopamine to activate them. It also affects serotonin 5HT2A receptors in the frontal cortex, which helps reduce unwanted side effects.

When to interrupt dosage

The suggested dosage of Zyprexa Relprevv is contingent upon the diagnosed affliction, including Schizophrenia, Bipolar Disorder and Delirium. The amount of dosage likewise varies, in line with the technique of delivery (e.g. Kit - Intramuscular or Tablet, film coated - Oral) as noted in the below table.

Condition

Dosage

Administration

Delusional Parasitosis

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Delirium

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Schizophrenia

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Schizophrenia

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Alzheimer's Disease

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Unipolar Depression

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Post Traumatic Stress Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Acute Agitation

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Mental Depression

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Acute Coryza

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Bipolar Disorder

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Gilles de la Tourette's Syndrome

2.5 mg, , 5.0 mg, 20.0 mg, 15.0 mg, 10.0 mg, 10.0 mg/mL, 7.5 mg, 3.0 mg, 6.0 mg, 12.0 mg, 210.0 mg, 300.0 mg, 405.0 mg, 405.0 mg/mL, 300.0 mg/mL, 210.0 mg/mL

, Oral, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, for solution, Intramuscular, Injection, powder, for solution - Intramuscular, Tablet - Oral, Tablet, Capsule, Capsule - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular, Powder, for solution, Powder, for solution - Intramuscular, Tablet, coated, Tablet, coated - Oral, Injection, powder, for suspension, extended release, Injection, powder, for suspension, extended release - Intramuscular, Kit - Intramuscular, Kit

Warnings

There are 20 known major drug interactions with Zyprexa Relprevv.

Common Zyprexa Relprevv Drug Interactions

Drug Name

Risk Level

Description

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Olanzapine.

Acepromazine

Major

Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Olanzapine is combined with Aclidinium.

Alfuzosin

Major

Olanzapine may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Olanzapine may increase the antipsychotic activities of Amisulpride.

Zyprexa Relprevv Toxicity & Overdose RiskTaking too much olanzapine can cause drowsiness, dilated pupils, slow breathing, low blood pressure, muscle stiffness, and dry mouth. Clinical trials have reported the maximum dose of olanzapine to be 300mg, which can cause slurred speech and drowsiness. However, reports of more serious side effects after taking higher doses of olanzapine, such as agitation, difficulty speaking, fast heartbeat, muscle stiffness, and loss of consciousness, have been noted. In one case, a person died after taking 450mg of olanzapine. Treatment for an overdose may include providing oxygen

Zyprexa Relprevv Novel Uses: Which Conditions Have a Clinical Trial Featuring Zyprexa Relprevv?

578 active clinical trials are exploring the potential of Zyprexa Relprevv in the management of Schizophrenia, Post Traumatic Stress Disorder and Delusional Parasitosis.

Condition

Clinical Trials

Trial Phases

Bipolar Disorder

0 Actively Recruiting

Gilles de la Tourette's Syndrome

0 Actively Recruiting

Bipolar Disorder

0 Actively Recruiting

Mental Depression

3 Actively Recruiting

Not Applicable

Delusional Parasitosis

0 Actively Recruiting

Acute Coryza

1 Actively Recruiting

Not Applicable

Delirium

49 Actively Recruiting

Phase 2, Not Applicable, Phase 3, Phase 4, Phase 1, Early Phase 1

Unipolar Depression

50 Actively Recruiting

Not Applicable, Phase 4, Early Phase 1, Phase 2, Phase 3, Phase 1

Schizophrenia

175 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Early Phase 1, Phase 4, Phase 1

Post Traumatic Stress Disorder

253 Actively Recruiting

Phase 4, Phase 1, Not Applicable, Early Phase 1, Phase 2, Phase 3

Acute Agitation

0 Actively Recruiting

Alzheimer's Disease

41 Actively Recruiting

Phase 2, Phase 3, Phase 4, Not Applicable, Phase 1

Schizophrenia

34 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Bipolar Disorder

1 Actively Recruiting

Phase 4

Patient Q&A Section about zyprexa relprevv

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long does Zyprexa IM injection last?

"Olanzapine extended-release injection is typically given once every 2 to 4 weeks. Olanzapine extended-release injection may help manage your symptoms but will not cure your condition."

Answered by AI

Is Zyprexa Relprevv still available?

"Because of the potential risks, ZYPREXA RELPREVV is only available through a restricted distribution program called the ZYPREXA RELPREVV Patient Care Program. This program requires enrollment of the prescriber, healthcare facility, patient, and pharmacy. [see Dosage and Administration (2.1), Warnings and Precautions (5.1, 5.2), Overdosage (10.2), and ..."

Answered by AI

How do you administer Zyprexa Relprevv?

"Zyprexa Relprevv should be administered by a healthcare professional every 2 to 4 weeks by deep intramuscular gluteal injection using a 19-gauge, 1.5-inch needle. Following insertion of the needle into the muscle, the healthcare professional should aspirate for several seconds to ensure that no blood is drawn into the syringe."

Answered by AI

How long does Zyprexa Relprevv last?

"Olanzapine as a pamoate monohydrate is a long-lasting injectable or depot form of olanzapine that provides another option for maintaining treatment of schizophrenia. It is administered by deep intramuscular gluteal injection only, every 2 weeks or every 4 weeks."

Answered by AI

Clinical Trials for Zyprexa Relprevv

Image of The University of Texas health Science Center at Houston in Houston, United States.

Bupropion +1 More for Smoking Cessation

This trial aims to test if giving a combination of injectable naltrexone and oral bupropion to individuals with schizophrenia who smoke cigarettes is safe and possible. They will also look at how

Waitlist Available

The University of Texas health Science Center at HoustonJin H Yoon, PhD

Image of UCSF Alliance Health Project in San Francisco, United States.

Cognitive Processing Therapy +1 More for Post-Traumatic Stress Disorder

San Francisco, CA

"This trial aims to determine if two types of therapy, Cognitive Processing Therapy and STAIR Narrative Therapy, are effective in treating posttraumatic stress disorder (PTSD) in LGBTQIA+ adults. The

Waitlist Available

UCSF Alliance Health ProjectAnnesa P Flentje, PhD

Image of VA Puget Sound Health Care System in Seattle, United States.

ERG, all participants for Post-Traumatic Stress Disorder

This trial aims to investigate if the electroretinogram (ERG) can be used as a biomarker to understand how selective serotonin reuptake inhibitors (SSRIs) like sertral

VA Puget Sound Health Care SystemRebecca Hendrickson, MD, PhD

Image of Light and Health Research Center in Menands, United States.

Light Exposure Tracker for Mild Cognitive Impairment

This trial aims to study how light affects our body clocks. Twenty healthy older adults will take part in a study where they will be exposed to different types of lighting to see how it impacts their daily rhythms

Light and Health Research CenterMariana Figueiro, PhD

Have you considered Zyprexa Relprevv clinical trials? We made a collection of clinical trials featuring Zyprexa Relprevv, we think they might fit your search criteria.

Explore trials for Zyprexa Relprevv

Image of The University of Texas Health Science Center, Houston in Houston, United States.

Active H-coil rTMS for Schizophrenia

This trial will test if using a type of magnetic stimulation can help improve the brain's white matter in patients with schizophrenia spectrum disorder.

Waitlist Available

The University of Texas Health Science Center, HoustonXiaoming Du, PhD

Image of Toronto Western Hospital in Toronto, Canada.

Psilocybin for Depression

Toronto, Canada

This trial will test if one or two doses of psilocybin can help patients with treatment-resistant depression. It will investigate which dosing is more effective in relieving depressive symptoms and if a second

Toronto Western HospitalJoshua Rosenblat, MD, MSc

Image of University of Wisconsin in Madison, United States.

Stimulation mode first for Post-Traumatic Stress Disorder

This trial aims to understand how sleep quality, emotions, and daily mood affect PTSD in young people. Participants will have 4 study visits, including assessments, cognitive tests, surveys, and sleep studies with

Waitlist Available

University of WisconsinStephanie Jones, MD, PhD

Image of Temple University in Philadelphia, United States.

Behavior Activation for Schizoaffective Disorder

Philadelphia, PA

This trial aims to test a new program to help people with serious mental illness become more active and involved in their communities. Participants will attend weekly online sessions for 10 weeks and then monthly sessions for

Temple University

Have you considered Zyprexa Relprevv clinical trials? We made a collection of clinical trials featuring Zyprexa Relprevv, we think they might fit your search criteria.

Explore trials for Zyprexa Relprevv

Image of Teva Investigational Site 15726 in Marlton, United States.

Olanzapine for Schizophrenia

This trial aims to understand how the body processes three different forms of olanzapine and to assess their safety and tolerability. It also seeks to evaluate how ZYPREXA is processed in the body

Teva Investigational Site 15726Teva Medical Expert, MDTeva Branded Pharmaceutical Products R&D, Inc.

Image of Teva Investigational Site 15739 in Los Alamitos, United States.

TV-44749 for Schizophrenia

Los Alamitos, CA

This trial aims to compare how well TV-44749 works when given as a shot under the skin versus when taken as a pill (ZYPREXA®) in people with schizophrenia. It will also

Teva Investigational Site 15739 (+5 Sites)Teva Medical Expert, MDTeva Branded Pharmaceutical Products R&D, Inc.

Image of NYU Langone Health in New York, United States.

STAIR-NT for Substance Abuse

This trial aims to adapt a PTSD intervention for individuals with stimulant-opioid polysubstance use. The intervention will be integrated into a methadone maintenance treatment program in New York City. The

Waitlist Available

NYU Langone Health (+2 Sites)Amanda Bunting

Image of UNC Chapel Hill Medical Center in Chapel Hill, United States.

Psilocybin for Major Depressive Disorder

Chapel Hill, NC

"This trial aims to test how effective psilocybin-assisted therapy is in treating depression. Participants will undergo screening, receive psilocybin treatment, and attend follow-up sessions over a year.

UNC Chapel Hill Medical CenterRobert K McClure, MD

Have you considered Zyprexa Relprevv clinical trials? We made a collection of clinical trials featuring Zyprexa Relprevv, we think they might fit your search criteria.

Explore trials for Zyprexa Relprevv

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

Back to top

Terms of Service Privacy Policy Security